Literature DB >> 27467921

GITR drives TH9-mediated antitumor immunity.

Il-Kyu Kim1, Yeonseok Chung2, Chang-Yuil Kang1.   

Abstract

TH9 cells have been implicated in triggering antitumor immunity. We have identified that GITR co-stimulation inhibits iTreg cell generation but drives TH9 cell differentiation, thereby suppressing tumor growth via enhancing the function of DCs and CTLs in vivo. Our findings provide novel mechanisms by which GITR agonists exert antitumor activity.

Entities:  

Keywords:  Antitumor immunity; GITR; IL-9; TH9 cell; iTreg cell

Year:  2015        PMID： 27467921      PMCID： PMC4910720          DOI： 10.1080/2162402X.2015.1122862

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity.

Authors:  R F Wang
Journal:  Trends Immunol       Date:  2001-05       Impact factor: 16.687

Review 2.  Th9 cells, new players in adaptive immunity.

Authors:  Edgar Schmitt; Matthias Klein; Tobias Bopp
Journal:  Trends Immunol       Date:  2013-11-08       Impact factor: 16.687

Review 3.  Modulation of GITR for cancer immunotherapy.

Authors:  David A Schaer; Judith T Murphy; Jedd D Wolchok
Journal:  Curr Opin Immunol       Date:  2012-01-12       Impact factor: 7.486

4.  Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.

Authors:  Rafael Carretero; Ibrahim M Sektioglu; Natalio Garbi; Oscar C Salgado; Philipp Beckhove; Günter J Hämmerling
Journal:  Nat Immunol       Date:  2015-04-27       Impact factor: 25.606

5.  Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells.

Authors:  Il-Kyu Kim; Byung-Seok Kim; Choong-Hyun Koh; Jae-Won Seok; Jun-Seok Park; Kwang-Soo Shin; Eun-Ah Bae; Ga-Eun Lee; Hyewon Jeon; Jaebeom Cho; Yujin Jung; Daehee Han; Byoung S Kwon; Ho-Young Lee; Yeonseok Chung; Chang-Yuil Kang
Journal:  Nat Med       Date:  2015-08-17       Impact factor: 53.440

6.  Th9 cells promote antitumor immune responses in vivo.

Authors:  Yong Lu; Sungyoul Hong; Haiyan Li; Jungsun Park; Bangxing Hong; Lijuan Wang; Yuhuan Zheng; Zhiqiang Liu; Jingda Xu; Jin He; Jing Yang; Jianfei Qian; Qing Yi
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

Review 7.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

Review 8.  Th2-mediated anti-tumour immunity: friend or foe?

Authors:  J I Ellyard; L Simson; C R Parish
Journal:  Tissue Antigens       Date:  2007-07

9.  Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells.

Authors:  Rahul Purwar; Christoph Schlapbach; Sheng Xiao; Hong Soon Kang; Wassim Elyaman; Xiaodong Jiang; Anton M Jetten; Samia J Khoury; Robert C Fuhlbrigge; Vijay K Kuchroo; Rachael A Clark; Thomas S Kupper
Journal:  Nat Med       Date:  2012-07-08       Impact factor: 53.440

10.  GITR subverts Foxp3(+) Tregs to boost Th9 immunity through regulation of histone acetylation.

Authors:  Xiang Xiao; Xiaomin Shi; Yihui Fan; Xiaolong Zhang; Minhao Wu; Peixiang Lan; Laurie Minze; Yang-Xin Fu; Rafik M Ghobrial; Wentao Liu; Xian Chang Li
Journal:  Nat Commun       Date:  2015-09-14       Impact factor: 14.919
  10 in total
  1 in total

Review 1.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.